Forskning
Udskriv Udskriv
Switch language
Region Hovedstaden - en del af Københavns Universitetshospital
Udgivet

IL-8 as antibody therapeutic target in inflammatory diseases: reduction of clinical activity in palmoplantar pustulosis

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

Harvard

Skov, L, Beurskens, FJ, Zachariae, COC, Reitamo, S, Teeling, J, Satijn, D, Knudsen, K, Boot, EPJ, Hudson, D, Baadsgaard, O, Parren, PWHI & van de Winkel, JGJ 2008, 'IL-8 as antibody therapeutic target in inflammatory diseases: reduction of clinical activity in palmoplantar pustulosis' Journal of immunology (Baltimore, Md. : 1950), bind 181, nr. 1, s. 669-79.

APA

CBE

Skov L, Beurskens FJ, Zachariae COC, Reitamo S, Teeling J, Satijn D, Knudsen K, Boot EPJ, Hudson D, Baadsgaard O, Parren PWHI, van de Winkel JGJ. 2008. IL-8 as antibody therapeutic target in inflammatory diseases: reduction of clinical activity in palmoplantar pustulosis. Journal of immunology (Baltimore, Md. : 1950). 181(1):669-79.

MLA

Vancouver

Author

Skov, Lone ; Beurskens, Frank J ; Zachariae, Claus O C ; Reitamo, Sakari ; Teeling, Jessica ; Satijn, David ; Knudsen, Kim ; Boot, Elmieke P J ; Hudson, Debra ; Baadsgaard, Ole ; Parren, Paul W H I ; van de Winkel, Jan G J. / IL-8 as antibody therapeutic target in inflammatory diseases : reduction of clinical activity in palmoplantar pustulosis. I: Journal of immunology (Baltimore, Md. : 1950). 2008 ; Bind 181, Nr. 1. s. 669-79.

Bibtex

@article{711e03c1e7664a5a9b71a01cf4a4da61,
title = "IL-8 as antibody therapeutic target in inflammatory diseases: reduction of clinical activity in palmoplantar pustulosis",
abstract = "IL-8 is a chemokine that has been implicated in a number of inflammatory diseases involving neutrophil activation. HuMab 10F8 is a novel fully human mAb against IL-8, which binds a discontinuous epitope on IL-8 overlapping the receptor binding site, and which effectively neutralizes IL-8-dependent human neutrophil activation and migration. We investigated whether interference in the cytokine network by HuMab 10F8 might benefit patients suffering from palmoplantar pustulosis, a chronic inflammatory skin disease. Treatment of patients with HuMab 10F8 was well tolerated and significantly reduced clinical disease activity at all five endpoints, which included a >or=50{\%} reduction in the formation of fresh pustules. IL-8 neutralization was monitored at the site of inflammation by assessing exudates of palmoplantar pustulosis lesions. HuMab 10F8 sequestered IL-8 in situ, as observed by rapid dose-dependent decreases of IL-8 concentrations immediately following Ab infusion. These data demonstrate a critical role for IL-8 in the pathophysiology of palmoplantar pustulosis. HuMab 10F8 is capable of interrupting IL-8 activity in vivo and represents a candidate for treatment of inflammatory diseases and other pathological conditions associated with IL-8 overproduction.",
keywords = "Amino Acid Sequence, Animals, Antibodies, Monoclonal, Cells, Cultured, Epitopes, Humans, Immune Tolerance, Immunotherapy, Inflammation, Interleukin-8, Mice, Mice, Transgenic, Models, Molecular, Molecular Sequence Data, Neutrophils, Protein Binding, Protein Structure, Tertiary, Psoriasis, Time Factors",
author = "Lone Skov and Beurskens, {Frank J} and Zachariae, {Claus O C} and Sakari Reitamo and Jessica Teeling and David Satijn and Kim Knudsen and Boot, {Elmieke P J} and Debra Hudson and Ole Baadsgaard and Parren, {Paul W H I} and {van de Winkel}, {Jan G J}",
year = "2008",
month = "7",
day = "1",
language = "English",
volume = "181",
pages = "669--79",
journal = "Journal of Immunology",
issn = "0022-1767",
publisher = "American Association of Immunologists",
number = "1",

}

RIS

TY - JOUR

T1 - IL-8 as antibody therapeutic target in inflammatory diseases

T2 - reduction of clinical activity in palmoplantar pustulosis

AU - Skov, Lone

AU - Beurskens, Frank J

AU - Zachariae, Claus O C

AU - Reitamo, Sakari

AU - Teeling, Jessica

AU - Satijn, David

AU - Knudsen, Kim

AU - Boot, Elmieke P J

AU - Hudson, Debra

AU - Baadsgaard, Ole

AU - Parren, Paul W H I

AU - van de Winkel, Jan G J

PY - 2008/7/1

Y1 - 2008/7/1

N2 - IL-8 is a chemokine that has been implicated in a number of inflammatory diseases involving neutrophil activation. HuMab 10F8 is a novel fully human mAb against IL-8, which binds a discontinuous epitope on IL-8 overlapping the receptor binding site, and which effectively neutralizes IL-8-dependent human neutrophil activation and migration. We investigated whether interference in the cytokine network by HuMab 10F8 might benefit patients suffering from palmoplantar pustulosis, a chronic inflammatory skin disease. Treatment of patients with HuMab 10F8 was well tolerated and significantly reduced clinical disease activity at all five endpoints, which included a >or=50% reduction in the formation of fresh pustules. IL-8 neutralization was monitored at the site of inflammation by assessing exudates of palmoplantar pustulosis lesions. HuMab 10F8 sequestered IL-8 in situ, as observed by rapid dose-dependent decreases of IL-8 concentrations immediately following Ab infusion. These data demonstrate a critical role for IL-8 in the pathophysiology of palmoplantar pustulosis. HuMab 10F8 is capable of interrupting IL-8 activity in vivo and represents a candidate for treatment of inflammatory diseases and other pathological conditions associated with IL-8 overproduction.

AB - IL-8 is a chemokine that has been implicated in a number of inflammatory diseases involving neutrophil activation. HuMab 10F8 is a novel fully human mAb against IL-8, which binds a discontinuous epitope on IL-8 overlapping the receptor binding site, and which effectively neutralizes IL-8-dependent human neutrophil activation and migration. We investigated whether interference in the cytokine network by HuMab 10F8 might benefit patients suffering from palmoplantar pustulosis, a chronic inflammatory skin disease. Treatment of patients with HuMab 10F8 was well tolerated and significantly reduced clinical disease activity at all five endpoints, which included a >or=50% reduction in the formation of fresh pustules. IL-8 neutralization was monitored at the site of inflammation by assessing exudates of palmoplantar pustulosis lesions. HuMab 10F8 sequestered IL-8 in situ, as observed by rapid dose-dependent decreases of IL-8 concentrations immediately following Ab infusion. These data demonstrate a critical role for IL-8 in the pathophysiology of palmoplantar pustulosis. HuMab 10F8 is capable of interrupting IL-8 activity in vivo and represents a candidate for treatment of inflammatory diseases and other pathological conditions associated with IL-8 overproduction.

KW - Amino Acid Sequence

KW - Animals

KW - Antibodies, Monoclonal

KW - Cells, Cultured

KW - Epitopes

KW - Humans

KW - Immune Tolerance

KW - Immunotherapy

KW - Inflammation

KW - Interleukin-8

KW - Mice

KW - Mice, Transgenic

KW - Models, Molecular

KW - Molecular Sequence Data

KW - Neutrophils

KW - Protein Binding

KW - Protein Structure, Tertiary

KW - Psoriasis

KW - Time Factors

M3 - Journal article

VL - 181

SP - 669

EP - 679

JO - Journal of Immunology

JF - Journal of Immunology

SN - 0022-1767

IS - 1

ER -

ID: 45972241